Journal article · 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
New England Journal of Medicine, 395(4), 325–337 · Published 31 May 2026 · DOI 10.1056/nejmoa2605555
In brief
“Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer” is a 2026 journal article by Eileen Mary O'Reilly and 19 co-authors, published in New England Journal of Medicine. OpenAlex counts 202 citations as of 16 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 202
- Most cited in
- 2026 (201)
- Field-weighted impact
- 481.71
- References
- 30
- Authors
- 20
Abstract
BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
O'Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P. R., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido‐Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine, 395(4), 325–337. https://doi.org/10.1056/nejmoa2605555
MLA 9
O'Reilly, Eileen Mary, et al. “Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.” New England Journal of Medicine, vol. 395, no. 4, 2026, pp. 325–337. https://doi.org/10.1056/nejmoa2605555.
Chicago
O'Reilly, Eileen Mary, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal R. Hammel, et al. 2026. “Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.” New England Journal of Medicine 395 (4): 325–337. https://doi.org/10.1056/nejmoa2605555.
Harvard
O'Reilly, E. M. et al. (2026) ‘Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer’, New England Journal of Medicine, 395(4), pp. 325–337. doi:10.1056/nejmoa2605555.
IEEE
E. M. O'Reilly et al., “Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer,” New England Journal of Medicine, vol. 395, no. 4, pp. 325–337, 2026, doi: 10.1056/nejmoa2605555.
BibTeX
@article{oreilly2026daraxonrasib,
title = {{Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer}},
author = {O'Reilly, Eileen Mary and Wainberg, Zev A. and Hendifar, Andrew E. and Borad, Mitesh J. and Pietrantonio, Filippo and Pant, Shubham and Hammel, Pascal R. and Cremolini, Chiara and Manji, Gulam Abbas and Oberstein, Paul E. and Garrido‐Laguna, Ignacio and Springfeld, Christoph and Azad, Nilofer Saba and Ueno, Makoto and Chui, Stephen Y. and Zhang, Ying and Patel, Hina and Lee, Yeonju and Salman, Zeena and Wolpin, Brian Matthew},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {4},
pages = {325--337},
doi = {10.1056/nejmoa2605555},
url = {https://doi.org/10.1056/nejmoa2605555}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- daraxonrasib
- metastatic pancreatic ductal adenocarcinoma
- RAS inhibitors
- previously treated patients
- chemotherapy comparison
- overall survival
- progression-free survival
- adverse events
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
O'Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P. R., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido‐Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine, 395(4), 325–337. https://doi.org/10.1056/nejmoa2605555
How many times has this paper been cited?
202 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Eileen Mary O'Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal R. Hammel, Chiara Cremolini, Gulam Abbas Manji, Paul E. Oberstein, Ignacio Garrido‐Laguna, Christoph Springfeld and 8 more.
What is the DOI of this paper?
10.1056/nejmoa2605555, permanently at https://doi.org/10.1056/nejmoa2605555. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.